(This story has been updated to provide commentary from company executives on the results.)
CV Sciences, a CBD specialist based in Las Vegas, reported revenue of $14.9 million for its first quarter ended March 31, up 85% from the same period a year ago.
Net loss for the quarter was $9.4 million, compared with net income of $600,000 the prior year as the company expanded retail operations and recorded higher payroll and compensation expenses.
CV Sciences’ topical CBD products have been included in the mainstream retail wave, appearing in roughly 800 CVS stores at the end of the first quarter.
However, “CVS shipments did not contribute significantly to Q1 revenue,” CFO Joerg Grasser said on a conference call to discuss the results.
The company likely won’t see strong results from the agreement for a quarter or two, according to CEO Joseph Dowling, because there is often a lag between launch and results.
Convenience stores also remain a target for the company, as an “interesting opportunity, and we are pursuing it aggressively,” Dowling said.
CV Sciences continues to pursue a listing on the Nasdaq, but for now trades on over-the-counter markets under the ticker symbol CVSI.
To read more about CV Sciences’ latest earnings report, click here.
Subscribe to our Newsletter
MJShareholders.com is the largest dedicated financial network and leading corporate communications firm serving the legal cannabis industry. Our network aims to connect public marijuana companies with these focused cannabis audiences across the US and Canada that are critical for growth: Short and long term cannabis investors Active funding sources Mainstream media Business leaders Cannabis consumers